Compare Vaxcyte Inc. Common Stock (PCVX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Financial Select Sector SPDR Fund trades at $54.87 (market cap $52.24B). The key difference: Financial Select Sector SPDR Fund is far larger — about 5× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| PCVX | XLF | |
|---|---|---|
Market Cap | $10.51B | $52.24B |
Volume | 2,644,694 | 44,490,388 |
Sector | Health | — |
52-Week High | $73.82 | $58.55 |
52-Week Low | $40.32 | $47.80 |
Typical Hold Time | 0 Days | 104 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLF trades at $54.82, down 0.42% amid mixed technical signals with a bullish moving average trend but neutral oscillators. The ETF faces sector headwinds as financial stocks lag the broader market despite rising bank profits. Recent Federal Reserve stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The financial sector ETF shows potential for benefiting from rising interest rates, though regulatory uncertainty and market underperformance relative to the S&P 500 present near-term risks. Institutional rotation into financials in Q2 2026 suggests confidence in the sector's rate sensitivity advantages over technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
